Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROAD-EURASIA: Effect of Dapagliflozin on Renin-Aldosterone System in Hypertensive Type 2 Diabetes
jRCTs031180272Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of dapagliflozin in type 2 diabetes mellitus (T2DM) and hypertension (HTN) (2 arms), sponsored by Ono Pharmaceutical. Primary endpoint: Plasma renin activity (PRA). Started Mar 2017; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)hypertension (HTN)
Beyond the preview
Go deeper on jRCTs031180272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180272.